The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Guardant Health Inc (NASDAQ: GH) was $40.64 for the day, down -5.71% from the previous closing price of $43.10. In other words, the price has decreased by -$5.71 from its previous closing price. On the day, 2.28 million shares were traded. GH stock price reached its highest trading level at $42.86 during the session, while it also had its lowest trading level at $39.7201.
Ratios:
Our analysis of GH’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.36 and its Current Ratio is at 4.68.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on January 23, 2025, initiated with a Overweight rating and assigned the stock a target price of $60.
On June 28, 2024, Guggenheim Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $36.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 03 ’25 when Joyce Meghan V. sold 100 shares for $42.71 per share. The transaction valued at 4,271 led to the insider holds 7,647 shares of the business.
Joyce Meghan V. bought 100 shares of GH for $4,271 on Mar 03 ’25. On Feb 20 ’25, another insider, Tariq Musa, who serves as the Director of the company, sold 116 shares for $48.33 each. As a result, the insider received 5,606 and left with 3,078 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 5015829504 and an Enterprise Value of 5511921152. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.79. Its current Enterprise Value per Revenue stands at 7.458 whereas that against EBITDA is -13.738.
Stock Price History:
The Beta on a monthly basis for GH is 1.44, which has changed by 1.290868 over the last 52 weeks, in comparison to a change of 0.07903516 over the same period for the S&P500. Over the past 52 weeks, GH has reached a high of $50.89, while it has fallen to a 52-week low of $15.81. The 50-Day Moving Average of the stock is -3.84%, while the 200-Day Moving Average is calculated to be 27.80%.
Shares Statistics:
GH traded an average of 2.35M shares per day over the past three months and 2595440 shares per day over the past ten days. A total of 123.99M shares are outstanding, with a floating share count of 118.00M. Insiders hold about 4.39% of the company’s shares, while institutions hold 96.28% stake in the company. Shares short for GH as of 1740700800 were 7897769 with a Short Ratio of 3.36, compared to 1738281600 on 5771757. Therefore, it implies a Short% of Shares Outstanding of 7897769 and a Short% of Float of 6.670000399999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Guardant Health Inc (GH) is currently under the scrutiny of 15.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.55, with high estimates of -$0.3 and low estimates of -$0.88.
Analysts are recommending an EPS of between -$1.11 and -$3.39 for the fiscal current year, implying an average EPS of -$2.15. EPS for the following year is -$1.69, with 16.0 analysts recommending between -$0.14 and -$2.89.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 18 analysts. It ranges from a high estimate of $199M to a low estimate of $186M. As of the current estimate, Guardant Health Inc’s year-ago sales were $168.49MFor the next quarter, 18 analysts are estimating revenue of $205.43M. There is a high estimate of $209.2M for the next quarter, whereas the lowest estimate is $202M.
A total of 22 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $865.74M, while the lowest revenue estimate was $842.4M, resulting in an average revenue estimate of $855.41M. In the same quarter a year ago, actual revenue was $739.02MBased on 22 analysts’ estimates, the company’s revenue will be $1.04B in the next fiscal year. The high estimate is $1.09B and the low estimate is $976.4M.
